Funding injection for Cryolife's bioadhesive
This article was originally published in Clinica
Executive Summary
Cryolife (US) expects to begin human trials of the bioadhesive, BioGlue, in the final quarter next year, following animal trials which are scheduled to finish in September 1996. Funding of $100,000 toward the trials has been awarded by the US Department of Health and Human Services. The plasma protein-based bioadhesive could replace sutures and staples in certain surgical procedures, believes Cryolife.